Monte Rosa Therapeutics (NASDAQ:GLUE) Receives Outperform Rating from Wedbush
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report released on Thursday, MarketBeat.com reports. They presently have a $17.00 price target on the stock, up from their prior price target of $15.00. Wedbush’s target price suggests a potential upside of 193.10% from […]
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report released on Thursday, MarketBeat.com reports. They presently have a $17.00 price target on the stock, up from their prior price target of $15.00. Wedbush’s target price suggests a potential upside of 193.10% from […]
